Case Report

Perianal Plasmoacanthoma After BCG-Immunotherapy: Case Report and Review of Literature


Plasmoacanthoma is a rare verrucous tumor classified as a form of reactive plasmacytosis. We present the first reported case of plasmoacanthoma following exposure to bacillus Calmette-Guérin (BCG) and a comprehensive review of the literature to better illustrate the patients’ characteristics and proposed risk factors, clinical features, diagnosis, treatment, and outcome of current reports. A 64-year-old female presented with a perianal hyperkeratotic plaque and diffused inflammatory macerated erosions in the intergluteal cleft and adjacent to the plaque after intravesical BCG immunotherapy. Laboratory studies disclosed systemic abnormalities and local infection or malignancies. Biopsy showed intradermal polyclonal plasma cell infiltration with acanthosis. The lesions were successfully treated with carbon dioxide laser ablation followed by the combination of pulsed dye laser and intralesional corticosteroid. Diagnosis of cutaneous reactive plasmacytosis should be confirmed by excluding the systemic causes of plasmacytosis and malignancies. It responds well to intralesional corticosteroids; however, in severe cases and large sizes, other treatments such as carbon dioxide laser ablation and pulsed dye laser should be considered as a combined therapy. Identification of causative factors is impractical while skin irritants with subsequent inflammation seem to be involved; as in the current report, BCG contact with skin initialized the pathologic process.

1. James WD BT, Elston DM. Disorders of the mucous membranes: Plasma cell cheilitis, plasmoacanthoma. In: James WD BT, Elston DM, ed. Andrews’ Diseases of the Skin. Philadelphia: Elsevier Saunders; 2011:785.
2. Rocha N, Mota F, Horta M, Lima O, Massa A, Sanches M. Plasma cell cheilitis. J Eur Acad Dermatol Venereol. 2004;18(1):96-98.
3. White JW, Olsen KD, Banks PM. Plasma cell orificial mucositis: report of a case and review of the literature. Arch Dermatol. 1986;122(11):1321-1324.
4. Senol M, Ozcan A, Aydin NE, Hazneci E, Turan N. Intertriginous plasmacytosis with plasmoacanthoma: report of a typical case and review of the literature. Int J Dermatol. 2008;47(3):265-268.
5. Van de Kerkhof P, Van Baar H. Co-occurrence of plasma cell orificial mucositis and plasmoacanthoma. Dermatology. 1995;191(1):52-55.
6. Curto CR, Chaves MY, Morán AG, Asensio PG, López G. Plasma cell gingivitis. CUTIS-NEW YORK-. 2002;69(1):41-45.
7. Bharti R, Smith DR. Mucous membrane plasmacytosis: a case report and review of the literature. Dermatol Online J. 2003;9(5).
8. Aiba S, Tagami H. Immunoglobulin‐producing cells in plasma cell orificial mucositis. J Cutan Pathol. 1989;16(4):207-210.
9. Doyle E, Crew J, Mostafid H, et al. Urothelial cancer: a narrative review of the role of novel immuno‐therapeutic agents with particular reference to the management of non‐muscle invasive disease. BJU Int. 2018.
10. Garcia C, Jina H, Bergersen P, Chalasani V. Bladder Contracture–A Rare and Serious Side Effect of Intravesical Bacillus Calmette-Guérin Therapy. Urol Case Rep. 2016;4:22-24.
11. Hirayama T, Matsumoto K, Tsuboi T, et al. Anaphylactoid purpura after intravesical therapy using bacillus Calmette-Guerin for superficial bladder cancer. Hinyokika kiyo Acta Urol Jap. 2008;54(2):127-129.
12. Kureshi F, Kalaaji AN, Halvorson L, Pittelkow MR, Davis MD. Cutaneous complications of intravesical treatments for bladder cancer: granulomatous inflammation of the penis following BCG therapy and penile gangrene following mitomycin therapy. J Am Acad Dermatol. 2006;55(2):328-331.
13. Suster S, Ronnen M, Huszar M, Pines A, Schibi-Brilliant G. Induction of cutaneous plasma cell tumor as a complication of adjuvant immunotherapy with methanol extraction residue of bacillus Calmette-Guerin. Oncology. 1987;44(5):279-282.
14. Ferreira-Marques J. Beitrag zur Kenntnis der Plasmocytosis circumorificialis (Schuermann)“Plasmoakanthoma”. Arch Klin Exp Dermatol. 1962;215(2):151-164.
15. Ramos E SJ. Das Plasmoakanthoma. Hautarzt. 1965;16:7–11.
16. Göring H, Linse R, Jäger K, Raschke N. Plasmoacanthoma. A contribution to the diagnosis, etiopathogenesis and nosology. Z Hautkr. 1985;60(11):884-896.
17. Roh HS, Jeong MG, Choi WJ, Jue MS, Ko JY, Ro YS. Plasmoacanthomas at both angles of mouth treated with carbon dioxide laser ablation. J Dermat. 2013;40(3):217-219.
18. Khatri G, Mahajan VK, Chauhan PS, Mehta KS, Chander B, Gupta M. Plasmoacanthoma of oral cavity and plasma cell cheilitis: two sides of same disorder “oral plasma cell mucositis”? Our Dermatol Online. 2014;5(2):172.
19. Braga BB, Michalany AO, Oliveira Filho Jd, Cucé LC. Plasmoacanthoma. An Bras Dermatol. 2016;91(5):128-130.
20. Mamalis A, Ho D, Parsi KK, Jagdeo J. Successful Treatment of Actinic Granuloma With Pulsed-Dye Laser and Fractionated Carbon Dioxide Laser. Dermatol Surg. 2018;44(3):452-454.
IssueVol 60, No 6 (2022) QRcode
SectionCase Report(s)
Plasmoacanthoma Reactive plasmacytosis Bacillus calmette-guérin (BCG) Plasma cell Mucocutaneous BCG-immunotherapy

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
Roohaninasab M, Goodarzi A, Chalangari R, Martits-Chalangari K, Haddadi N-S, Mansouri P. Perianal Plasmoacanthoma After BCG-Immunotherapy: Case Report and Review of Literature. Acta Med Iran. 2022;60(6):375-381.